Eligible patients had KRAS G12C mutations confirmed by histologic or blood-based testing, an ECOG performance status of 0 or 1, and measurable disease per RECIST v1.1. The primary end points were the incidence of dose-limiting toxicities (DLTs), adverse effects (AEs), and AEs leading to discontinuation. Secondary end points included ORR and DOR per RECIST v1.1 by investigator assessment and pharmacokinetics; PFS was an exploratory end point.
What did earlier KANDLELIT-001 results show for calderasib plus pembrolizumab in NSCLC?
Results from KANDLELIT-001 were previously presented at the 2026 European Lung Cancer Congress.2,3 In that analysis, calderasib plus pembrolizumab elicited an ORR of 72% (95% CI, 63%-81%) and a median PFS of 28.9 months (95% CI, 20.6-NR) among patients with a TPS of 1% or higher (n = 98). Among patients with a TPS of 50% or higher (n = 54), the ORR was 87% (95% CI, 75%-95%) and the median PFS was NR. Calderasib monotherapy produced an ORR of 27% (95% CI, 16%-40%) among patients with NSCLC (n = 59), and in the triplet arm (n = 46), the median PFS was 15.1 months (95% CI, 10.5-NR).
How did calderasib monotherapy and the triplet regimen perform in KRAS G12C–mutated NSCLC?
Among efficacy-evaluable patients with previously treated NSCLC who received calderasib monotherapy (n = 103) in the updated analysis, the ORR was 35% (95% CI, 26%-45%) and the DCR was 78% (95% CI, 68%-85%).1 The median DOR was 16.8 months (range, 1.2+ to 36.1+), and the median PFS was 8.3 months (95% CI, 6.0-16.4), with 6- and 12-month PFS rates of 62% and 40%, respectively.
In the triplet arm (n = 46), calderasib plus pembrolizumab and chemotherapy produced an ORR of 65% (95% CI, 50%-79%) and a DCR of 89% (95% CI, 76%-96%). The median DOR was 19.4 months (range, 1.9+ to 27.4+), and the median PFS was 17.6 months (95% CI, 10.5-26.3); the 6- and 12-month PFS rates were 82% and 66%, respectively.
What was the safety profile of calderasib-based regimens in KANDLELIT-001?
Any-grade treatment-related adverse effects (TRAEs) occurred in 61% of patients in the monotherapy arms, which included all solid tumors (n = 271); 89% of patients in arm 2 (n = 136); and 98% of patients in arm 4 (n = 46). Grade 3 TRAEs occurred in 7%, 25%, and 59% of patients, respectively, and grade 4 TRAEs occurred in less than 1%, 4%, and 11%. One patient in arm 2 had grade 5 treatment-related myelosuppression and decreased platelet count, and 1 patient in arm 4 had grade 5 treatment-related immune-mediated myositis; no treatment-related deaths occurred with monotherapy.
TRAEs led to calderasib discontinuation in 1%, 4%, and 7% of patients in the monotherapy, doublet, and triplet arms, respectively, and to pembrolizumab discontinuation in 24% of patients in arm 2 and 30% of those in arm 4. The most common TRAEs with calderasib plus pembrolizumab were increased aspartate aminotransferase levels (AST; 35%), increased alanine transaminase levels (ALT; 32%), and pruritus (27%); with the triplet, they were anemia (48%), increased ALT (43%), and increased AST (43%). DLTs occurred in 1% of evaluable patients in the monotherapy arms (n = 107), 6% in arm 2 (n = 34), and 11% in arm 4 (n = 46).
What are the next steps for calderasib plus pembrolizumab in first-line KRAS G12C–mutated NSCLC?
The investigators concluded that the findings support enrollment in 2 ongoing phase 3 trials of calderasib plus pembrolizumab as first-line therapy for KRAS G12C–mutated metastatic NSCLC. The randomized, double-blind, phase 3 KANDLELIT-004 trial (NCT06345729) is comparing calderasib plus pembrolizumab vs placebo plus pembrolizumab in patients with a TPS of 50% or higher. The randomized, open-label, phase 3 KANDLELIT-007 trial (NCT07190248) is comparing calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) vs subcutaneous pembrolizumab plus chemotherapy in patients with nonsquamous disease.
Disclosures: Şendur reported receiving payment or honoraria for lectures, presentations, or speakers bureaus from Roche, AstraZeneca, Pfizer, Novartis, Astellas, BMS, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD), Eli Lilly, Gilead, Takeda, Centurion, and Menarini Stemline; receiving support for meeting attendance and/or travel from Roche, Centurion, and Menarini; and participating on a data safety monitoring board or advisory board for Roche, AstraZeneca, Pfizer, Novartis, Astellas, BMS, MSD, Eli Lilly, Gilead, Takeda, Centurion, and Menarini Stemline.
References
- Gray JE, Peled N, Liu L, et al. Calderasib (MK-1084), alone or in combination, for KRAS G12C-mutant metastatic non-small cell lung cancer. Presented at: 2026 ESMO Congress; October 23-27, 2026; Madrid, Spain. Abstract 2680RO.
- Sacher A, Rottenberg Y, Kwiatkowski M, et al. Updated results for MK-1084 + pembrolizumab in KRAS G12C-mutated metastatic non–small-cell lung cancer enrolled in KANDLELIT-001. Presented at: 2026 European Lung Cancer Congress; March 25-28, 2026; Copenhagen, Denmark. Abstract 4MO.
- Seymour C. Calderasib-based therapy drives high responses in KRAS G12C–mutant metastatic NSCLC. OncLive. Published March 26, 2026. Accessed November 16, 2026. https://www.onclive.com/view/calderasib-based-therapy-drives-high-responses-in-kras-g12c-mutant-metastatic-nsclc